Valliant John's Form 4 filing
Fusion Pharmaceuticals Inc. (FUSN) · filed Mar 3, 2022
- Accession no.
- 0001209191-22-015555
- Filed
- Mar 3, 2022
- Trade date
- Mar 1-3, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $205.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valliant JohnCIK 0001813574 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | SSaleDisposed | −847 | $7.37F2 | −$6,242.39 | 431,536 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −26,546 | $7.44F3 | −$197,502.24 | 404,990 | Direct | |
| Mar 3, 2022 | Common Stock | SSaleDisposed | −200 | $7.28F4 | −$1,456 | 404,790 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.29 to $7.52 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.20 to $7.60 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.28 to $7.281 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.